Sanofi (SNY) Non-Current Debt (2009 - 2026)
Sanofi (SNY) posted Non-Current Debt of $17.0 billion for Q2 2026, up 2.64% sequentially from $16.6 billion in Q4 2025, and up 13.93% YoY from $14.9 billion in Q2 2025.
Sanofi (SNY) Non-Current Debt (2009 - 2026) Analysis & Trends
Sanofi has reported Non-Current Debt for 18 years, with the latest figure at $17.0 billion in Q2 2026.
- Quarterly Non-Current Debt rose 13.93% year-over-year to $17.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $17.0 billion (up 13.93% YoY) and the FY2025 annual result came in at $16.6 billion, up 31.63% from the prior year.
- Non-Current Debt grew to $17.0 billion in Q2 2026 per SNY's latest filing, from $16.6 billion in the prior quarter.
- Over five years, Non-Current Debt peaked at $17.0 billion in Q2 2026 and troughed at $12.6 billion in Q4 2024.
- A 5-year average of $15.3 billion and a median of $15.4 billion in 2023 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2025: Non-Current Debt retreated 22.62% in 2022, then soared 31.63% in 2025.
- Over 5 years, Non-Current Debt stood at $15.2 billion in 2022, then climbed by 1.84% to $15.4 billion in 2023, then fell by 18.38% to $12.6 billion in 2024, then jumped by 31.63% to $16.6 billion in 2025, then climbed by 2.64% to $17.0 billion in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $17.0 billion, $16.6 billion, and $14.9 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 23.68 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 57.30 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 26.25 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 60.50 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -18.71 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 17.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.02 Bn |
| Dec 31, 2025 | 16.59 Bn |
| Jun 30, 2025 | 14.94 Bn |
| Dec 31, 2024 | 12.60 Bn |
| Jun 30, 2024 | 13.46 Bn |
| Dec 31, 2023 | 15.44 Bn |
| Jun 30, 2023 | 15.51 Bn |
| Dec 31, 2022 | 15.16 Bn |
| Jun 30, 2022 | 17.01 Bn |
| Dec 31, 2021 | 19.59 Bn |
| Jun 30, 2021 | 21.60 Bn |
| Dec 31, 2020 | 23.54 Bn |
| Jun 30, 2020 | 22.47 Bn |
| Dec 31, 2019 | 22.28 Bn |
| Jun 30, 2019 | 23.69 Bn |
| Dec 31, 2018 | 25.12 Bn |
| Mar 31, 2018 | 26.36 Bn |
| Dec 31, 2017 | 16.87 Bn |
| Jun 30, 2017 | 16.70 Bn |
| Dec 31, 2016 | 18.16 Bn |